**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ESMO Ovarian | **Project Code** | PB4LSS023 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**Early November 2014**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

4-6 Weeks

**Cross Promotion**

Yes

No

If Yes, List Activities: probably a combined e-blast for all esmo webcasts

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By: after symposium

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

October

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

www.prIMEoncology.org/Ovarian\_Madrid\_2014Webcast

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Downloadable Slides From *Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on* BRCA *Biomarkers***

**ACTIVITY FEATURES**

**[Interactive Presentation]**

[Icon] Downloadable Slides

[CME-Certified]

[Insert screen shot]

**ACTIVITY OVERVIEW**

prIME Oncology invites you to view downloadable slides from Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on BRCA Biomarkers, a prIME Oncology educational activity that was held at the 2014 European Oncology Congress in Madrid, Spain, on 28 September 2014.

**PROVIDER**

This activity is provided by prIME Oncology.

**[Tab—Insert Disease Topic]**

Discussant: **Ignace Vergote, MD, PhD,** University Hospital Gasthuisberg, Leuven, Belgium

Topic: Treatment of advanced ovarian cancer: Guideline recommendations and unmet needs

* Learning Objective:
* Incorporate current guideline recommendations and recent data when devising personalized therapeutic plans for women with advanced ovarian cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Judith Balmaña, MD, PhD,** Vall d’Hebron University Hospital, Barcelona, Spain

Topic: Testing for *BRCA* gene mutations: Why, when, and for whom?

* Learning Objective:
* Integrate data from trials evaluating the significance of *BRCA* gene mutation and the role of testing this biomarker in the management of advanced ovarian cancer into clinical practice

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Susana Banerjee, MBBS, MA, MRCP, PhD,** Royal Marsden Hospital, London, United Kingdom

Topic: *BRCA*-associated ovarian cancer: How to personalize first-line and subsequent therapies?

* Learning Objective:
* Employ novel targeted strategies for *BRCA*-associated ovarian cancer when choosing optimal treatment regimens for patients with advanced ovarian cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

***Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on* BRCA *Biomarkers***

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] CME-Certified

**ACTIVITY OVERVIEW**

This CME-certified Webcast contains **video and downloadable slides** from the symposium Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on BRCA Biomarkers, a prIME Oncology educational activity that was held at the 2014 European Oncology Congress in Madrid, Spain, on 28 September.

**TOPICS**

Treatment of advanced ovarian cancer: Guideline recommendations and unmet needs

*Ignace Vergote, MD, PhD*

Testing for *BRCA* gene mutations: Why, when, and for whom?

*Judith Balmaña, MD, PhD*

*BRCA*-associated ovarian cancer: How to personalize first-line and subsequent therapies?

*Susana Banerjee, MBBS, MA, MRCP, PhD*

**FACULTY**

**Chair**

Ignace Vergote, MD, PhD

University Hospital Gasthuisberg

Leuven, Belgium

**Faculty**

Judith Balmaña, MD, PhD

Vall d’Hebron University Hospital

Barcelona, Spain

Susana Banerjee, MBBS, MA, MRCP, PhD

Royal Marsden Hospital

London, United Kingdom

**TARGET AUDIENCE**

This activity is intended for oncologists and other healthcare professionals who provide medical care for patients with advanced ovarian cancer.

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Incorporate current guideline recommendations and recent data when devising personalized therapeutic plans for women with advanced ovarian cancer
* Integrate data from trials evaluating the significance of *BRCA* gene mutation and the role of testing this biomarker in the management of advanced ovarian cancer into clinical practice
* Employ novel targeted strategies for *BRCA*-associated ovarian cancer when choosing optimal treatment regimens for patients with advanced ovarian cancer
* Refer eligible patients to enroll in clinical trials investigating novel targeted agents for treatment of advanced ovarian cancer

Insert objectives from live meeting

**CONTINUING MEDICAL EDUCATION [if applicable]**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of XX *AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**METHOD OF PARTICIPATION [if applicable]**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with XX% or higher.

**DISCLOSURES [if applicable]**

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Balmaña has disclosed that she received grants/research support from AstraZeneca and Biomarine. Furthermore she has received honoraria or consulting fees from AstraZeneca, Clovis and Myriad.

Dr Banerjee has disclosed that she received grants/research support from Janssen. Furthermore she has received honoraria or consulting fees from Roche and AstraZeneca (not personally renumerated).

Dr Vergote has disclosed that he has served as a consultant and/or advisory board for Amgen NV; Array Biopharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EISAI; Eli Lilly; Endocyte; Fresenius; GE Healthcare; Glaxo-SmithKline; Intuitive Surgical; Janssen-Cilag; Menarini Ricerche Spa; Merck Sharp & Dohme; Morphotek; Nektar Therapeutics; Novo Nordisk Pharma; Oasmia Pharmaceutical AB; Pharmamar; Philips Gilmore Oncology; Quintiles Belgium; Roche-Hoffmann; Sanofi-Aventis; Shering-Plough; Sigma-Tau Pharmaceuticals; Telik; and TRM Oncology BV.

The employees of prIME Oncology have disclosed: [[note: for Roche activities, only list Bojana, Trudy, and Regulatory/Compliance Manager]]

* Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
* Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
* Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**PROVIDER**

This activityis provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by AstraZeneca.

**ACTIVITY DATE**

Release Date: 3 November 2014

Expiration Date: 3 November 2015

**MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app.

1. **Web Activity Page Titles**

Landing Page Title: Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on *BRCA* Biomarkers  
Activity Page Title: Please us the Presentation titles

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.** This should be roughly 150 characters in length. This is the short description that will appear beneath the activity title in search results, so it should be a compelling, keyword-rich description that will encourage the user to click)

Webcast and downloadable slide presentations from thought leaders on the management of *BRCA*-related ovarian cancer.

1. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:**

ovarian cancer

BRCA

BRCA mutation

BRCA-related ovarian cancer

BRCA 1/2

PARP inhibitor

olaparib

genetic mutation

genetic testing

serous ovarian cancer

germline mutation

platinum-based therapy

homologous recombination

genetic counseling

DNA damage repair pathways

Platinum-sensitive

Partially platinum-sensitive

Platinum-resistant

Treatment algorithm

Bevacizumab

Maintenance

Rucaparib

Cediranib

1. **~~[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**

~~For each presentation:~~

~~Listing: City—Disease—Presenter~~

~~Description: [Name, degree(s)], from [Institution] discusses [insert topic description].~~